JP7429224B2 - Ｌｐａアンタゴニストとしてのシクロヘプチル酸 - Google Patents
Ｌｐａアンタゴニストとしてのシクロヘプチル酸 Download PDFInfo
- Publication number
- JP7429224B2 JP7429224B2 JP2021515027A JP2021515027A JP7429224B2 JP 7429224 B2 JP7429224 B2 JP 7429224B2 JP 2021515027 A JP2021515027 A JP 2021515027A JP 2021515027 A JP2021515027 A JP 2021515027A JP 7429224 B2 JP7429224 B2 JP 7429224B2
- Authority
- JP
- Japan
- Prior art keywords
- independently
- lpa
- alkyl
- cycloalkyl
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862732595P | 2018-09-18 | 2018-09-18 | |
| US62/732,595 | 2018-09-18 | ||
| PCT/US2019/051275 WO2020060916A1 (en) | 2018-09-18 | 2019-09-16 | Cycloheptyl acids as lpa antagonists |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022500469A JP2022500469A (ja) | 2022-01-04 |
| JP2022500469A5 JP2022500469A5 (https=) | 2023-11-08 |
| JPWO2020060916A5 JPWO2020060916A5 (https=) | 2023-11-08 |
| JP7429224B2 true JP7429224B2 (ja) | 2024-02-07 |
Family
ID=68073224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515027A Active JP7429224B2 (ja) | 2018-09-18 | 2019-09-16 | Ｌｐａアンタゴニストとしてのシクロヘプチル酸 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220041572A1 (https=) |
| EP (1) | EP3852747B1 (https=) |
| JP (1) | JP7429224B2 (https=) |
| KR (1) | KR102800284B1 (https=) |
| CN (1) | CN112702998A (https=) |
| ES (1) | ES2948793T3 (https=) |
| WO (1) | WO2020060916A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102788997B1 (ko) | 2018-09-18 | 2025-03-28 | 브리스톨-마이어스 스큅 컴퍼니 | Lpa 길항제로서의 옥사비시클로 산 |
| ES2946657T3 (es) * | 2018-09-18 | 2023-07-24 | Bristol Myers Squibb Co | Acidos ciclopentílicos como antagonistas de LPA |
| AU2020384883B2 (en) | 2019-11-15 | 2023-11-16 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as LPA receptor antagonists and uses thereof |
| TWI843503B (zh) | 2020-06-03 | 2024-05-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| CN115867556B (zh) | 2020-06-03 | 2025-05-06 | 吉利德科学公司 | Lpa受体拮抗剂及其用途 |
| TWI853704B (zh) | 2021-05-11 | 2024-08-21 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| KR20240007233A (ko) * | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| AR128613A1 (es) | 2022-02-25 | 2024-05-29 | Lhotse Bio Inc | Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad del receptor de lpa |
| CN121866249A (zh) | 2023-09-08 | 2026-04-14 | 海思科医药集团股份有限公司 | 一种lpar1拮抗剂及其用途 |
| WO2026061483A1 (zh) * | 2024-09-19 | 2026-03-26 | 西藏海思科制药有限公司 | 一种lpar1拮抗剂及其用途 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189864A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
| WO2017223016A1 (en) | 2016-06-21 | 2017-12-28 | Bristol-Myers Squibb Company | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
| JP2022500473A (ja) | 2018-09-18 | 2022-01-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| JP2022500470A (ja) | 2018-09-18 | 2022-01-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002062389A1 (en) | 2001-02-08 | 2002-08-15 | Ono Pharmaceutical Co., Ltd. | Remedies for urinary diseases comprising lpa receptor controlling agents |
| US20080186971A1 (en) | 2007-02-02 | 2008-08-07 | Tarari, Inc. | Systems and methods for processing access control lists (acls) in network switches using regular expression matching logic |
| TW201120016A (en) * | 2009-12-08 | 2011-06-16 | Abbott Lab | Novel oxadiazole compounds |
| EP2694472B1 (en) | 2011-04-05 | 2020-03-11 | Takeda Pharmaceutical Company Limited | Sulfonamide derivative and use thereof |
-
2019
- 2019-09-16 US US17/276,178 patent/US20220041572A1/en not_active Abandoned
- 2019-09-16 ES ES19779300T patent/ES2948793T3/es active Active
- 2019-09-16 WO PCT/US2019/051275 patent/WO2020060916A1/en not_active Ceased
- 2019-09-16 CN CN201980060422.9A patent/CN112702998A/zh active Pending
- 2019-09-16 KR KR1020217011086A patent/KR102800284B1/ko active Active
- 2019-09-16 JP JP2021515027A patent/JP7429224B2/ja active Active
- 2019-09-16 EP EP19779300.3A patent/EP3852747B1/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189864A1 (en) | 2012-06-20 | 2013-12-27 | F. Hoffmann-La Roche Ag | N-alkyltriazole compounds as lpar antagonists |
| WO2017223016A1 (en) | 2016-06-21 | 2017-12-28 | Bristol-Myers Squibb Company | Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists |
| JP2022500473A (ja) | 2018-09-18 | 2022-01-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 |
| JP2022500470A (ja) | 2018-09-18 | 2022-01-04 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Ｌｐａアンタゴニストとしてのシクロペンチル酸 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112702998A (zh) | 2021-04-23 |
| KR20210060547A (ko) | 2021-05-26 |
| WO2020060916A1 (en) | 2020-03-26 |
| EP3852747A1 (en) | 2021-07-28 |
| KR102800284B1 (ko) | 2025-04-23 |
| US20220041572A1 (en) | 2022-02-10 |
| JP2022500469A (ja) | 2022-01-04 |
| ES2948793T3 (es) | 2023-09-19 |
| EP3852747B1 (en) | 2023-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7202383B2 (ja) | Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸 | |
| JP7427658B2 (ja) | Ｌｐａアンタゴニストとしてのシクロペンチル酸 | |
| JP7429224B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘプチル酸 | |
| JP7256807B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアゾール | |
| JP7301840B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールｎ結合カルバモイルシクロヘキシル酸 | |
| JP7369125B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールｏ－架橋カルバモイルシクロヘキシル酸 | |
| JP7274486B6 (ja) | Ｌｐａアンタゴニストとしてのトリアゾールｎ結合カルバモイルシクロヘキシル酸 | |
| JP7301839B2 (ja) | Ｌｐａアンタゴニストとしてのピラゾールｎ－連結のカルバモイルシクロヘキシル酸 | |
| JP7526096B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン | |
| JP7412424B2 (ja) | Ｌｐａアンタゴニストとしてのオキサビシクロ酸 | |
| JP7299892B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン | |
| JP7465899B2 (ja) | Ｌｐａアンタゴニストとしてのシクロブチルカルボン酸 | |
| JP7212047B2 (ja) | Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール | |
| JP7422788B2 (ja) | Ｌｐａアンタゴニストとしてのイソキサゾールカルボン酸 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220831 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220831 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230810 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230912 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20231030 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231113 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240123 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240126 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7429224 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |